Reshaping the HIV treatment and prevention landscape
Delivering
growth:
2021-26
and beyond
More than 5% sales CAGR 2021-26
Transformed commercial capabilities and execution drive growth
Maximise priority Vaccines and Specialty Medicines in key growth markets
Optimise General Medicines portfolio for profitability and cash
Execution of late-stage pipeline to drive more than £33bn sales ambition by 2031
All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See
basis of preparation and assumptions in Appendix. CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of
new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the above.
26View entire presentation